Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
Portfolio Pulse from
Exelixis, Inc. announced positive results from a subgroup analysis of their Phase 3 CABINET study, showing that cabozantinib improved progression-free survival in patients with advanced gastrointestinal neuroendocrine tumors.
January 24, 2025 | 7:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis announced that cabozantinib improved progression-free survival in a subgroup of patients with advanced GI neuroendocrine tumors, as per the Phase 3 CABINET study results.
The announcement of positive results from a Phase 3 study is likely to boost investor confidence in Exelixis, as it suggests potential for cabozantinib in treating advanced GI neuroendocrine tumors. This could lead to increased interest in the stock, potentially driving the price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100